Author

K. Anders

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

T. Blankenstein· 2 shared A. Akalin· 1 shared A. Eggert· 1 shared A. G. Henssen· 1 shared A. Klaus· 1 shared A. Kuenkele· 1 shared A. Milojkovic· 1 shared A. Vitali· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

T. Blankenstein

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Oncogene inactivation-induced senescence facilitates tumor relapse

P. Schmitt, K. Hoenig, M. T. Norcia, M. F. Nogueira, V. Flore, I. S. Vesperinas, M. Villoro-Agud, L. Peng, Z. Safyuerek, M. Tariq, A. Milojkovic, K. Anders, E. Schroeck, S. Sauer, B. Uyar, , T. Blankenstein

This study shows that oncogene inactivation-induced senescence both limits tumor growth and promotes relapse by creating a pro-recurrence microenvironment.

Nature Communications · Jul 15, 2026Peer-reviewedCancer Biology

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

L. Grunewald, L. Andersch, K. Helmsauer, S. Schwiebert, A. Klaus, A. G. Henssen, T. Straka, M. Lodrini, S. G. Wicha, S. Fuchs, F. Hertwig, F. Westermann, A. Vitali, C. Caramel, G. Buechel, , A. Kuenkele

This paper shows that high MYCN levels in neuroblastoma reduce L1CAM expression, limiting CAR T cell efficacy, and that inhibiting MYCN with MLN8237 restores L1CAM and enhances CAR T cell activity.

bioRxiv · Jan 27, 2024Immunology